Vir Biotechnology VIR 深 沪
等待开盘 10-01 09:30:00 美东时间
11.175
+0.525
+4.93%
华盛通- 最 高11.258
- 今 开10.70
- 成交量 100.14万股
- 最 低 10.54
- 昨 收 10.65
- 总市值 18.91亿
- 52周最高 11.94
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 4.815
- 委 比 -57.50%
- 总股本 1.69亿
- 历史最高 141.01
- 量 比 0.69
- 振 幅 6.74%
- 历史最低 4.155
- 每 手 1
- 风险率 1.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst
Vir Biotechnology, Inc. ($VIR) announced an update on their ongoing clinical st...
08-20 00:30
Olema Oncology names Jason O’Byrne as CFO
Olema Pharmaceuticals (OLMA) has appointed Jason O’Byrne as chief financial officer. O’Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology a...
08-13 21:25
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Pharmaceuticals, Inc. ("Olema Oncology") announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. O’Byrne brings over 20 years of finance and global operations leadership in biotech and pharma. He previously served as CFO at Vir Biotechnology and Caribou Biosciences, leading financial and capital markets initiatives, including IPOs and acquisitions. Olema Oncology is advancing therapies for breast cancer, with palazestra...
08-13 11:00
Vir Biotechnology shares are trading higher after the company reported better-than-expected Q2 financial results.
Vir Biotechnology shares are trading higher after the company reported better-than-expected Q2 financial results.
08-06 20:54
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
Vir Biotechnology ( ($VIR) ) has issued an announcement. On July 20, 2026, Vir ...
07-24 20:57
Vir Biotechnology announces Chief Financial Officer transition
Vir Biotechnology (VIR) on Friday said Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed interim Principal Financial Officer, effective July 23. Jason O’Byrne is l...
07-24 20:39
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences appoints Dr. Mark Eisner to its Board of Directors. Eisner, with over 25 years of experience in clinical development and immunology, previously served as Chief Medical Officer at Vir Biotechnology, Sonoma Biotherapeutics, and FibroGen, and led global development programs at Genentech/Roche. Jade Biosciences focuses on developing best-in-class therapies for autoimmune diseases, with its pipeline including JADE101, JADE201, and JAD...
06-26 11:00
